Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Biosensors for inflammation as a strategy to engineer regulatory T cells for cell therapy (2022) Bittner S, Ruhland B, Hofmann V, Schmidleithner L, Schambeck K, Pant A, Stüve P, et al. Journal article Risk of pelvic metastasis and significance of pelvic lymphadenectomy in patients with node-positive vulvar cancer - results of the AGO-VOP.2/QS vulva study (2022) Jaeger A, Hampl M, Zu Eulenburg C, Prieske K, Hambrecht J, Fuerst S, Klapdor R, et al. Conference contribution Long-term survival of HER2-positive breast cancer patients with brain metastases: subanalysis of the BMBC Registry (2022) Laakmann E, Riecke K, Neunhoeffer T, Park-Simon TW, Weide R, Polasik A, Schmidt M, et al. Conference contribution Recombinant Human Cytomegalovirus Expressing an Analog-Sensitive Kinase pUL97 as Novel Tool for Functional Analyses (2022) Krämer N, Schütz M, Mato UG, Herhaus L, Marschall M, Zimmermann C Journal article Randomized Comparison of Intracoronary Lithotripsy and Rotational Atherectomy for the Treatment of Severely Calcified Vessels-ROTA.shock Trial (2022) Nef H, Schlattner S, Weissner M, Gori T, Ullrich H, Gaede L, Achenbach S, et al. Conference contribution BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours (2022) Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Heudobler D, Borchmann P, et al. Conference contribution Kidsafe-improving medication safety for children and adolescents: Implementation and evaluation of a new form of care (2022) Toni I, Koenig J, Makosi DM, Urschitz MS, Rascher W, Neubert A Conference contribution Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Meier F, Weichenthal M, Grimmel-Mann I, Gutzmer R, Utikal JS, et al. Conference contribution Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022) Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al. Conference contribution Patient preferences of German and Swiss melanoma patients with regard to life-threatening side effects in the context of adjuvant immunotherapy - a qualitative GerMelaTox-A substudy (2022) Peters W, Maul LV, Huning S, Hassel JC, Heinzerling L, Loquai C, Gutzmer R, et al. Conference contribution